NCT07378423 Questionnaire on Congenital Cancer Signs Through Self-Assessment
| NCT ID | NCT07378423 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Condition | Cancer Predisposition Syndromes |
| Study Type | INTERVENTIONAL |
| Enrollment | 205 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 205 participants in total. It began in 2026-04-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial tests whether a patient- and caregiver-completed questionnaire (QUOCCAS) can accurately help identify children and adolescents with cancer who may have an underlying cancer predisposition syndrome (CPS). The study will also evaluate whether providing families with an educational brochure before their clinic visit improves their understanding of genetics and their satisfaction with care. The main questions it aims to answer are: * Does QUOCCAS identify children at risk for CPS as accurately as physician-based tools and compared to genetic testing? * Does the Pre-Visit Preparation (PVP) brochure improve caregiver knowledge about genetics? * Does the PVP brochure improve caregiver satisfaction with the care and information they receive? Participants will: * Complete the QUOCCAS questionnaire about family history, clinical features, and cancer signs * Provide a blood or saliva sample for genetic testing (whole-exome or whole-genome sequencing) * Randomly receive or not receive the educational Pre-Visit Preparation brochure before completing the questionnaire * Complete brief surveys on their knowledge and satisfaction
Eligibility Criteria
Inclusion Criteria: * The investigators will include newly diagnosed patients who received a cancer diagnosis included in the International Classification of Childhood Cancer version 3 (ICCC3) criteria, treated at participating hospitals Exclusion Criteria: * Over 21 years of age
Contact & Investigator
Nicolas Waespe, MD PhD, PD
PRINCIPAL INVESTIGATOR
University Children's Hospital Bern, Inselspital, Bern, Switzerland
Frequently Asked Questions
Who can join the NCT07378423 clinical trial?
This trial is open to participants of all sexes, up to 21 Years, studying Cancer Predisposition Syndromes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07378423 currently recruiting?
Yes, NCT07378423 is actively recruiting participants. Contact the research team at quoccas@insel.ch for enrollment information.
Where is the NCT07378423 trial being conducted?
This trial is being conducted at Bern, Switzerland.
Who is sponsoring the NCT07378423 clinical trial?
NCT07378423 is sponsored by Insel Gruppe AG, University Hospital Bern. The principal investigator is Nicolas Waespe, MD PhD, PD at University Children's Hospital Bern, Inselspital, Bern, Switzerland. The trial plans to enroll 205 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.